MedTrace Logo

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

NCT05514548 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 265

Last updated 2025-08-11

No results posted yet for this study

Summary

The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus.

Conditions

  • Diabetic Kidney Disease

Interventions

DRUG

INV-202

INV-202 is a new generation of CB1R antagonist developed by Inversago for potential use as a therapeutic method for the treatment of metabolic disorders, including nonalcoholic steatohepatitis, diabetes and its complications (such as DKD), and hypertriglyceridemia.

DRUG

Placebo

Placebo Matching size and number of tablets

Sponsors & Collaborators

  • Worldwide Clinical Trials

    collaborator OTHER

  • Inversago Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • Glenn Crater, MD · Inversago Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-19
Primary Completion
2024-08-20
Completion
2024-09-03
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Georgia
  • Hungary
  • Israel
  • Mexico
  • Serbia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05514548 on ClinicalTrials.gov